ProPhase Labs Q3 net loss $5.1M; revenue down 65% to $8.4M; plans big capacity expansion

ProPhase Labs, Inc.

2023-Q3 EPS reported -$0.47 revenue$40,885,000

Q3 net loss $5.1M (-$0.30/sh) vs net income $1.0M ($0.06/sh) a year ago.
Revenue fell to $8.4M from $24.2M; gross margin dropped to 27.8% from 49.5%.
Adjusted EBITDA loss of $2.5M vs income of $6.3M in Q3 2022.
Cash & equivalents $3.3M (Dec 31, 2022: $17.4M); working capital $33.4M.
Pharmaloz capacity targets: $10M→$15M by year-end, over $75M in 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProPhase Labs, Inc. reported financial results for the three and nine months ended September 30, 2023.

Period: the three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.